Fusion Antibodies Plc (FAB) Price & Analysis

Compare

9 Followers

FAB Stock Chart & Stats

14.50p

0.15p(1.82%)

At close: Jan 09 4:00 PM EST

14.50p

0.15p(1.82%)

Day’s Range― - ―

52-Week Range5.60p - 21.00p

Previous CloseN/A

Volume21.95K

Average Volume (3M)1.16M

Market Cap

£18.44M

Enterprise Value16.90M

Total Cash (Recent Filing)£252.00K

Total Debt (Recent Filing)£388.00K

Price to Earnings (P/E)―

Beta-0.60

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding125,021,880

10 Day Avg. Volume2,164,859

30 Day Avg. Volume1,162,225

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)8.81

Price to Sales (P/S)3.00

P/FCF Ratio-4.29

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Outsourced CRO Business ModelA fee-for-service CRO model sells project-based R&D to biotech and pharma, providing diversified client revenue and lower fixed-asset needs. This asset-light model supports scalable service growth and repeatable project pipelines, offering durable revenue visibility over months.

Low Leverage / Stable Capital StructureMinimal debt reduces financial risk and interest burden, preserving flexibility to fund operations or invest via equity or internal cash. A ~50% equity ratio indicates a stable solvency base, which helps the company withstand episodic revenue dips without immediate refinancing pressure.

Improving Gross Margin And RevenueA rebound in revenue combined with a higher gross margin suggests improved service mix, pricing, or operational efficiency. If sustained, these trends can drive operating leverage and narrow losses, supporting a multi-month path toward break-even at the operating level.

Bears Say

Deeply Negative Return On EquityAn ROE of -256% signals severe and persistent losses that erode shareholder equity, reducing ability to self-fund growth and increasing likelihood of dilution or external capital needs. This structural profitability gap limits strategic flexibility over the medium term.

Negative Operating Cash FlowCore operations currently consume cash rather than generate it, constraining internal funding for projects, payroll and capital requirements. Persistent negative OCF forces reliance on financing or equity raises, a durable risk that can impair execution and strategic investments.

Severe Net And EBIT Margin DeficitsExtremely negative EBIT and net margins show the business currently cannot cover operating fixed costs from revenues. Without structural cost reduction or higher-margin contracts, the company faces long-term profitability barriers that threaten sustainability and growth plans.

Fusion Antibodies Plc News

Rathbones Takes 7.74% Stake in Fusion Antibodies

Fusion Antibodies Plc ( ($GB:FAB) ) has issued an update. Fusion Antibodies plc reported that Rathbones Investment Management...

13d ago

Fusion Antibodies Confirms Total Voting Rights at 125 Million Shares

Fusion Antibodies Plc ( ($GB:FAB) ) has provided an update. Fusion Antibodies plc has confirmed that its issued...

18d ago

Fusion Antibodies Pays Executive Bonuses in Shares as Part of Cost-Conscious Strategy

Fusion Antibodies Plc ( ($GB:FAB) ) just unveiled an update. Fusion Antibodies plc has issued 308,720 new ordinary...

21d ago

Fusion Antibodies Raises £1.4m to Accelerate OptiMAL® Commercial Rollout

Fusion Antibodies Plc ( ($GB:FAB) ) has issued an announcement. Fusion Antibodies plc has conditionally raised approximately £1.4...

21d ago

Fusion Antibodies in Talks to Extend NCI Collaboration on OptiMAL Platform

Fusion Antibodies Plc ( ($GB:FAB) ) has issued an update. Fusion Antibodies has reported that the US National...

2M ago

Fusion Antibodies Launches OptiMAL® Human Antibody Discovery Platform

An update from Fusion Antibodies Plc ( ($GB:FAB) ) is now available. Fusion Antibodies plc has officially launched...

2M ago

Fusion Antibodies to Launch Innovative Antibody Discovery Platform

Fusion Antibodies Plc ( ($GB:FAB) ) has issued an announcement. Fusion Antibodies plc announced the upcoming commercial launch...

2M ago

Fusion Antibodies Reports Progress Amidst Revenue Decline

Fusion Antibodies Plc ( ($GB:FAB) ) has provided an announcement. Fusion Antibodies plc reported a reduction in losses...

3M ago

Fusion Antibodies to Release Interim Results and Host Investor Presentation

Fusion Antibodies Plc ( ($GB:FAB) ) has issued an announcement. Fusion Antibodies plc announced it will release its...

3M ago

Fusion Antibodies Unveils OptiMAL® Library Video Ahead of December Launch

Fusion Antibodies Plc ( ($GB:FAB) ) has shared an announcement. Fusion Antibodies plc has released a video featuring...

3M ago

FAB FAQ

What was Fusion Antibodies Plc’s price range in the past 12 months?

Fusion Antibodies Plc lowest share price was 5.60p and its highest was 21.00p in the past 12 months.

What is Fusion Antibodies Plc’s market cap?

Fusion Antibodies Plc’s market cap is £18.44M.

When is Fusion Antibodies Plc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Fusion Antibodies Plc’s earnings last quarter?

Currently, no data Available

Is Fusion Antibodies Plc overvalued?

According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fusion Antibodies Plc pay dividends?

Fusion Antibodies Plc does not currently pay dividends.

What is Fusion Antibodies Plc’s EPS estimate?

Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fusion Antibodies Plc have?

Fusion Antibodies Plc has 125,021,880 shares outstanding.

What happened to Fusion Antibodies Plc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Fusion Antibodies Plc?

Currently, no hedge funds are holding shares in GB:FAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fusion Antibodies Plc

Fusion Antibodies Plc (FAB) is a biotechnology company specializing in the development and production of fully human monoclonal antibodies. The company operates primarily in the life sciences sector, providing a range of services including antibody discovery, engineering, and development. Fusion Antibodies focuses on offering tailored solutions to pharmaceutical and biotechnology companies, helping them accelerate their drug discovery processes and enhance the efficacy of therapeutic antibodies.